Normal serum CA19-9 |
High serum CA19-9 |
p-value | |
---|---|---|---|
No. of patients | 184 (93.9%) | 12 (6.1%) | |
Age, years a | 47 (16-89) | 38.5 (18-87) | 0.531 |
Gender: | |||
Male | 45 (24.5%) | 3 (25.0%) | 0.975 |
Female | 139 (75.5%) | 9 (75.0%) | |
Max. tumor size, mm a | 26 (20-110) | 33 (20-61) | 0.130 |
Anti-thyroglobulin antibody: | |||
Positive | 32 | 1 | 0.695 |
Negative | 152 | 11 | |
Serum thyroglobulin levels before surgery, ng/mL a,b | 59.8 (2.0-2684) | 122.0 (1.0-1875) | 0.400 |
Serum thyroglobulin levels after surgery, ng/mL a,b | 1.2 (0.1-185) | 2.3 (0.3-377.7) | 0.308 |
Extrathyroidal invasion: | |||
Positive | 10 | 2 | 0.287 |
Negative | 174 | 10 | |
Nodal metastasis: | |||
Positive | 159 | 11 | 0.249 |
Negative | 25 | 1 | |
Vascular invasion: | |||
Positive | 10 | 1 | 0.512 |
Negative | 174 | 11 | |
Lymphangial invasion: | |||
Positive | 4 | 2 | 0.046 |
Negative | 180 | 10 | |
Ki-67 labeling index: | |||
0%-5% | 119 | 8 | |
5%-10% | 37 | 2 | 0.567 |
>10% | 5 | 1 | |
Unknown | 23 | 1 | |
Serum level of CA19-9, U/mL: a | |||
Before surgery | 11.2 (1-36.3) | 60.5 (40.8-221) | <0.01 |
After surgery | 9.0 (1-29.5) | 32.5 (17.5-36) | <0.01 |
Serum levels of CA19-9 | |||
---|---|---|---|
High >37 U/mL |
Normal ≤37 U/mL |
||
CA19-9 | Positive | 12 | 16 |
Immunohistochemistry | Negative | 0 | 34 |